{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "exchange": "NYQ", "shortName": "Eli Lilly and Company", "currency": "USD", "marketState": "REGULAR", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "regularMarketChangePercent": -0.47303194, "gmtOffSetMilliseconds": -14400000, "esgPopulated": false, "regularMarketPrice": 432.375, "longName": "Eli Lilly and Company", "messageBoardId": "finmb_285467", "market": "us_market", "fiftyTwoWeekLowChangePercent": 0.5272333, "fiftyTwoWeekRange": "283.11 - 445.54", "fiftyTwoWeekHighChange": -13.165009, "fiftyTwoWeekHighChangePercent": -0.029548433, "fiftyTwoWeekLow": 283.11, "fiftyTwoWeekHigh": 445.54, "dividendDate": 1686268800, "earningsTimestamp": 1691497800, "earningsTimestampStart": 1691497800, "earningsTimestampEnd": 1691497800, "trailingAnnualDividendRate": 4.07, "trailingPE": 68.63095, "trailingAnnualDividendYield": 0.009368598, "epsTrailingTwelveMonths": 6.3, "epsForward": 12.27, "epsCurrentYear": 8.73, "priceEpsCurrentYear": 49.527493, "sharesOutstanding": 949273024, "bookValue": 12.444, "fiftyDayAverage": 364.8516, "fiftyDayAverageChange": 67.52341, "fiftyDayAverageChangePercent": 0.18507089, "twoHundredDayAverage": 344.92276, "twoHundredDayAverageChange": 87.45224, "twoHundredDayAverageChangePercent": 0.25354153, "marketCap": 411849752576, "forwardPE": 35.238384, "priceToBook": 34.74566, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "firstTradeDateMilliseconds": 76253400000, "priceHint": 2, "regularMarketChange": -2.0549927, "regularMarketTime": 1684171504, "regularMarketDayHigh": 435.94, "regularMarketDayRange": "430.67 - 435.94", "regularMarketDayLow": 430.67, "regularMarketVolume": 1175288, "regularMarketPreviousClose": 434.43, "bid": 431.77, "ask": 431.97, "bidSize": 14, "askSize": 8, "fullExchangeName": "NYSE", "financialCurrency": "USD", "regularMarketOpen": 435.37, "averageDailyVolume3Month": 3326763, "averageDailyVolume10Day": 3930990, "fiftyTwoWeekLowChange": 149.26501, "symbol": "LLY"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "Lilly Corporate Center", "city": "Indianapolis", "state": "IN", "zip": "46285", "country": "United States", "phone": "317 276 2000", "website": "https://www.lilly.com", "industry": "Drug Manufacturers\u2014General", "industryDisp": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.", "fullTimeEmployees": 39000, "companyOfficers": [{"maxAge": 1, "name": "Mr. David A. Ricks", "age": 54, "title": "Chairman, CEO & Pres", "yearBorn": 1968, "fiscalYear": 2022, "totalPay": {"raw": 4416885, "fmt": "4.42M", "longFmt": "4,416,885"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anat  Ashkenazi", "age": 49, "title": "Exec. VP & CFO", "yearBorn": 1973, "fiscalYear": 2022, "totalPay": {"raw": 2125270, "fmt": "2.13M", "longFmt": "2,125,270"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Daniel M. Skovronsky M.D., Ph.D.", "age": 48, "title": "Exec. VP, Chief Scientific & Medical Officer and Pres of Lilly Research Laboratories", "yearBorn": 1974, "fiscalYear": 2022, "totalPay": {"raw": 2716346, "fmt": "2.72M", "longFmt": "2,716,346"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Anat  Hakim J.D.", "age": 53, "title": "Exec. VP, Gen. Counsel & Sec.", "yearBorn": 1969, "fiscalYear": 2022, "totalPay": {"raw": 1979674, "fmt": "1.98M", "longFmt": "1,979,674"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Patrik  Jonsson", "age": 55, "title": "EVP, Chief Customer Officer, Pres of Lilly USA & Lilly Immunology", "yearBorn": 1967, "fiscalYear": 2022, "totalPay": {"raw": 1673270, "fmt": "1.67M", "longFmt": "1,673,270"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Donald A. Zakrowski", "title": "Chief Accounting Officer & VP of Fin.", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Diogo  Rau", "title": "EVP & Chief Information and Digital Officer", "fiscalYear": 2021, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Alonzo  Weems", "age": 51, "title": "EVP of Enterprise Risk Management and Chief Ethics & Compliance Officer", "yearBorn": 1971, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Leigh Ann Pusey", "age": 59, "title": "Exec. VP of Corp. Affairs & Communications", "yearBorn": 1963, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Eric  Dozier", "age": 55, "title": "Exec. VP of HR & Diversity", "yearBorn": 1967, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "auditRisk": 3, "boardRisk": 5, "compensationRisk": 1, "shareHolderRightsRisk": 9, "overallRisk": 5, "governanceEpochDate": 1682899200, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}